Our portfolio companies benefit from our ongoing support and from the global network of our affiliates
Mirae Asset Capital Life Science
Pioneering a new class of small molecule precision cancer therapies targeting critical intracellular dependencies that span multiple types of cancer.
Developing transformative drugs beginning with bispecific T-cell engager (TCE) antibodies that deplete specific B cells in patients with autoimmune disease.
Mirae Asset Affiliates
(limited selection of representative companies)
= exited/public
Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha adiopharmaceuticals for the mainstream of cancer care.
BioNTech is committed to improving the health of people worldwide with their fundamental research and development of immunotherapies.
Septerna has assembled a team that thrives on innovation, combining pioneering GPCR scientists with experienced drug hunters.
Crossbow Therapeutics is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.
Vividion is a biopharmaceutical unlocking traditionally undruggable targets with precision small molecule therapeutics.
Sonoma Biotherapeutics develops engineered regulatory T-cell therapies to treat autoimmune & inflammatory diseases driven by an imbalanced immune system.
Arcellx is pursuing a cure for cancer. With their technology, they are reimagining cell therapy and supercharging how the world treats cancer.
Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine.
TCR2 develops a wide range of cell therapies for solid tumors as well as blood cancers by targeting a number of different surface antigens on cancer cells that have beneficial expression characteristics.